一、董事会会议召开情况 1、吉林敖东药业集团股份有限公司（以下简称"公司"）第十一届董事会 第二十二次会议通知以书面方式于 2025 年 12 月 1 日发出。 2、会议于 2025 年 12 月 5 日在公司六楼会议室以现场结合通讯方式召开。 证券代码：000623 证券简称：吉林敖东 公告编号:2025-067 吉林敖东药业集团股份有限公司 第十一届董事会第二十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 生 6 名董事为本次员工持股计划参与人，故对本项议案回避表决。 详见 2025 年 12 月 6 日在《证券时报》《上海证券报》《中国证券报》《证券 日报》及巨潮资讯网（http://www.cninfo.com.cn）披露的《关于公司员工持 股计划延期的公告》（公告编号：2025-068）。 三、备查文件 1、公司第十一届董事会第二十二次会议决议； 3、本次会议公司应到董事 9 名，实际参加会议董事 9 名，其中：独立董事 李鹏先生、肖维维女士、张春颖女士以通讯表决方式出席本次会议。 4、会议由公司董事长李秀林先生主持，公司高级管理 ...

Core Viewpoint - The Chinese traditional medicine sector is experiencing increased activity due to a surge in flu cases, with the Chinese Medicine ETF (560080) showing a slight decline but still attracting investor interest [1][9]. Market Performance - The Chinese Medicine ETF (560080) closed down 0.91% today, remaining in a consolidation phase, with a trading volume exceeding 84 million yuan, a 7% increase from the previous trading day [1]. - The ETF's closing premium rate was 0.06%, indicating ongoing investor attention, with two out of the last five days seeing inflows [1]. - The ETF's latest scale reached 2.598 billion yuan, leading its peers in the same category [1]. Stock Performance - Most constituent stocks of the Chinese Medicine ETF closed in the red, with notable declines including: - Pianzaihuang down 1.59% to 168.75 yuan, marking a five-year low [3]. - Yiling Pharmaceutical down over 3%, and Zhongsheng Pharmaceutical down over 2% [3]. - Conversely, stocks like Yunnan Baiyao and Jilin Aodong saw slight increases [3]. Valuation Metrics - As of December 3, the TTM price-to-earnings (PE) ratio for the ETF's index was 25.12, positioned at the 23.11% percentile over the past decade, suggesting that the index is cheaper than 76% of the time historically [5]. - The TTM PE is just 0.38 away from the calculated opportunity value, indicating a potential entry point for investors [5]. Historical Performance - The year-to-date return for the Chinese Medicine Index remains negative at -2.24%, with a decline of 8.13% projected for 2024 [7]. - The index has shown a pattern of consecutive declines, with four consecutive negative years if 2023 is considered a down year [7]. Demand Drivers - The recent flu outbreak has led to a significant increase in demand for respiratory medications, with flu cases reported rising by 53.8% compared to the previous week [9]. - The flu activity is at its highest level since 2022, which is expected to boost the demand for related medications [9]. Industry Outlook - Analysts from Zheshang Securities predict an inflection point for the Chinese medicine sector, suggesting that the sector will attract more investment due to its stable cash flow and lower volatility compared to other sectors [9]. - The industry is expected to see improved revenue and net profit growth in the second half of 2025, aided by reduced cost pressures from declining raw material prices [9].

Group 1 - The core viewpoint of the news highlights the strong performance of the Traditional Chinese Medicine (TCM) sector, driven by supportive government policies aimed at innovation and industrial transformation [1][2] - The Shanghai government has issued a document encouraging collaboration among medical institutions, research units, and pharmaceutical companies to create platforms for TCM innovation and industrial transformation [1] - The document supports the development of major TCM varieties and the secondary development of classic varieties, as well as the establishment of mechanisms for collecting and organizing human experience data for drug registration [1] Group 2 - China Galaxy Securities anticipates that policy-driven changes will continue to propel the pharmaceutical industry towards innovation and upgrades, with a focus on finding incremental opportunities in niche markets [2] - The report indicates that domestic innovative drugs are expected to yield results, with several second-generation I/O drugs and ADCs entering phase three clinical trials, which is promising for future developments [2] - The TCM prescription drug market is facing clinical re-evaluation, which may reshape the market landscape and potentially lead to a turning point in TCM gross margins [2] Group 3 - The TCM ETF closely tracks the Zhongzheng TCM Index, which selects listed companies involved in TCM production and sales to reflect the overall performance of TCM concept stocks [2] - As of October 31, 2025, the top ten weighted stocks in the Zhongzheng TCM Index account for 54.92% of the index, including companies like Yunnan Baiyao and Tongrentang [2]

Group 1 - The core point of the article is that Jilin Aodong (SZ 000623) held its 11th Board of Directors meeting on November 24, 2025, to discuss the election of members for the specialized committees of the board [1] - For the first half of 2025, Jilin Aodong's revenue composition was as follows: 73.63% from the pharmaceutical industry, 16.59% from wholesale and retail of chain pharmacies, 7.39% from food, 1.76% from other industries, and 0.62% from other businesses [1] - As of the report date, Jilin Aodong's market capitalization was 22.7 billion yuan [1] Group 2 - The article also mentions that Dapeng Industrial's strategic placement benefited its insiders, with a subscription price of 9 yuan and a first-day listing price of 118 yuan, resulting in a floating profit of 24.92 million yuan for the actual controller and his brother [1]

北京市京都（大连）律师事务所 法律意见书 北京市京都（大连）律师事务所 关于吉林敖东药业集团股份有限公司 召开 2025 年第二次临时股东会 之 法 律 意 见 书 致：吉林敖东药业集团股份有限公司 北京市京都（大连）律师事务所（以下简称"本所"）接受吉林敖东药业集团股 份有限公司（以下简称"公司"）的委托，指派本所律师 王秀宏、杨姗姗 出席公司 2025 年第二次临时股东会（以下称"本次股东会"）。本所律师根据《中华人民共和 国公司法》（以下简称《公司法》）、中国证监会《上市公司股东会规则》（以下简 称《股东会规则》）和《吉林敖东药业集团股份有限公司章程》（以下简称《公司章 程》）的相关规定，就公司本次股东会的召集与召开程序、出席会议人员与召集人的 资格、议案的提出、表决程序和结果等事宜的合法性、有效性进行见证并出具法律意 见。 公司保证和承诺其已经向本所律师提供了为出具本法律意见书所必需的、真实的 原始书面材料、电子邮件；有关副本材料、复印件与原件一致；公司对所提供的文件 资料的合法性和有效性承担法律责任。 本所律师根据对事实的了解和对法律的理解发表法律意见。 本所律师同意公司将本法律意见书作为本次股东会 ...

证券代码：000623 证券简称：吉林敖东 公告编号：2025-065 吉林敖东药业集团股份有限公司 2025年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决议案的情形。 2、本次股东会无变更以往股东会已通过决议的情形。 一、会议召开和出席情况 （一）召开情况 1、会议召开的时间： （1）现场会议召开的时间：2025年11月24日14:00。 （2）网络投票时间： 通过深圳证券交易所系统进行网络投票的具体时间为2025年11月24日 9:15-9:25，9:30-11:30，13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为2025年11月24日 9:15至15:00的任意时间。 2、召开地点：吉林省敦化市敖东大街2158号公司办公楼六楼会议室 3、表决方式：现场投票与网络投票相结合的方式 4、召集人：吉林敖东药业集团股份有限公司董事会 股份数 422,263,219 股，占公司有表决权股份总数 1,172,381,587 股（有表决 权股份总数指股权登记日的总股本 1,1 ...

证券代码：000623 证券简称：吉林敖东 公告编号:2025-066 吉林敖东药业集团股份有限公司 第十一届董事会第二十一次会议决议公告 1、审议《关于选举公司第十一届董事会专门委员会成员的议案》 根据《上市公司治理准则》及公司《董事会审计委员会实施细则》《董事会 提名委员会实施细则》的相关规定，现选举张春颖为公司第十一届董事会审计委 员会主任委员、第十一届董事会提名委员会委员，变更后的公司第十一届董事会 审计委员会、第十一届董事会提名委员会成员如下： 审计委员会主任：张春颖（独立董事） 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、吉林敖东药业集团股份有限公司（以下简称"公司"）第十一届董事会 第二十一次会议通知以书面方式于 2025 年 11 月 24 日发出。 2、会议于 2025 年 11 月 24 日在公司六楼会议室以现场结合通讯方式召开。 3、本次会议公司应到董事 9 名，实际参加会议董事 9 名，其中：独立董事 李鹏先生以通讯表决方式出席本次会议。 4、会议由公司董事长李秀林先生主持，公司高级管理人员列席本次董事会 ...

Core Viewpoint - Jilin Aodong's stock price has experienced a continuous decline, with a 5.09% drop on November 21, leading to a total market value of 22.72 billion yuan and a cumulative decline of 6.23% over five days [1] Group 1: Company Overview - Jilin Aodong Pharmaceutical Group Co., Ltd. was established on March 20, 1993, and listed on October 28, 1996 [1] - The company is primarily engaged in the research, development, manufacturing, and sales of traditional Chinese medicine, biochemical drugs, and is also expanding into health food, food, breeding, and planting sectors [1] - The revenue composition of the company includes: Traditional Chinese medicine 60.90%, chain pharmacy wholesale and retail 16.59%, chemical drugs 12.73%, food 7.39%, other products 1.76%, and others (supplementary) 0.62% [1] Group 2: Fund Holdings - One fund under China Merchants Fund holds a significant position in Jilin Aodong, specifically the China Merchants CSI 500 Equal Weight Index Enhanced A (009726), which reduced its holdings by 127,400 shares in the third quarter [2] - The current holding of the fund is 502,000 shares, accounting for 1% of the fund's net value, ranking as the seventh largest holding [2] - The fund has incurred a floating loss of approximately 512,000 yuan today and a total floating loss of 667,700 yuan during the five-day decline [2] Group 3: Fund Performance - The China Merchants CSI 500 Equal Weight Index Enhanced A (009726) was established on December 23, 2020, with a current scale of 480 million yuan [2] - Year-to-date return for the fund is 25.18%, ranking 1853 out of 4208 in its category; the one-year return is 22.47%, ranking 1726 out of 3972; and since inception, the return is 63.59% [2] - The fund manager, Cai Zhen, has been in position for 4 years and 110 days, with the best fund return during this period being 48.94% and the worst being 4.31% [3]

11月21日，吉林敖东跌5.09%，截至发稿，报19.00元/股，成交4.83亿元，换手率2.10%，总市值227.22 亿元。吉林敖东股价已经连续5天下跌，区间累计跌幅6.23%。 责任编辑：小浪快报 南方中证500ETF（510500）成立日期2013年2月6日，最新规模1400.98亿。今年以来收益25.25%，同类 排名1845/4208；近一年收益19.65%，同类排名2062/3972；成立以来收益137.65%。 南方中证500ETF（510500）基金经理为罗文杰。 截至发稿，罗文杰累计任职时间12年217天，现任基金资产总规模1704.45亿元，任职期间最佳基金回报 148.26%， 任职期间最差基金回报-47.6%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 资料显示，吉林敖东药业集团股份有限公司位于吉林省敦化市敖东大街2158号，成立日期1993年3月20 日，上市日期1996年10月28日，公司主营业务涉及中成药、生物化学药研发、制造和销售, ...

Macro Strategy - Recent international gold prices are fluctuating at high levels, with domestic jewelry gold prices also remaining elevated. There is a new trend in gold consumption favoring lighter products like gold bars. Short-term gold prices are expected to maintain high volatility. Consumers should pay attention to international gold price fluctuations if investing, and choose purchasing timing based on their budget for wearing needs [2][3] - From January to October, the national general public budget revenue reached 18.649 trillion yuan, a year-on-year increase of 0.8%. The national general public budget expenditure was 22.5825 trillion yuan, a year-on-year increase of 2%. Securities transaction stamp duty revenue was 162.9 billion yuan, a year-on-year increase of 88.1% [2] - By the end of 2024, the total asset scale of urban commercial banks in China is projected to be 60.15 trillion yuan, a 134-fold increase since 1995, accounting for 13.53% of the banking financial institutions, with a market share increase of 8.24 percentage points. The non-performing loan ratio is 1.76%, and the provision coverage ratio is 188.08% [2] Industry and Company Medical Services Industry - The medical and biological sector rose by 3.29%, ranking fifth among the 31 first-level industries. The Shanghai and Shenzhen 300 Index fell by 1.08%, indicating that the medical sector outperformed the index by 4.37 percentage points [6] - The PE (ttm) of the medical services sector is 33.47X, with a PB (lf) of 3.37X. The PE increased by 0.51X and the PB increased by 0.05X compared to the previous week [7][8] - The TIDES CRDMO market is expected to grow significantly, with the global market projected to increase from 2.1 billion USD in 2018 to 5.5 billion USD in 2023, with a CAGR of 20.9%, and further to 37.3 billion USD by 2032, with a CAGR of 23.8%. The Chinese market is expected to grow from 200 million USD in 2018 to 800 million USD in 2023, with a CAGR of 37.1%, and to 6.2 billion USD by 2032, with a CAGR of 25.5% [9] - Investment recommendations for the medical services sector include focusing on high-growth companies in the ADC CDMO and TIDES CDMO areas, as well as companies in the third-party testing laboratories and consumer medical sectors [10] Traditional Chinese Medicine Industry - The traditional Chinese medicine sector rose by 4.08%, ranking third among secondary sub-sectors. Companies such as Te Yi Pharmaceutical and Zhongsheng Pharmaceutical performed well, while others like *ST Changyao and ST Huluwa performed poorly [12] - The PE (ttm) for the traditional Chinese medicine sector is 29.25X, with a PB (lf) of 2.47X, indicating a slight increase from the previous week [13][14] - The market for traditional Chinese medicinal materials is experiencing volatility, with an overall supply surplus due to increased arrivals from new harvests. Recent weather conditions have also impacted harvesting [15] - The steady advancement of centralized procurement in the traditional Chinese medicine industry aims to reduce patient medication costs and shift competition towards cost control and quality standards [16][17] - Investment recommendations for the traditional Chinese medicine sector include focusing on companies with competitive advantages in product quality and cost, as well as those benefiting from national reforms and centralized procurement policies [18][19]